SI SHOULDER INNOVATIONS, INC.
FY2025 10-K
SHOULDER INNOVATIONS, INC. (SI) filed its fiscal year 2025 10-K annual report with the SEC on Mar 10, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Medical technology company focused exclusively on shoulder surgical care with integrated ecosystem including implants, AI-based preoperative planning, and specialized support
- • New product launches in 2025-2026: InSet 70 humeral stem, metal sensitivity implants (FDA cleared Jan 2026), and development of a shoulder-specific robotics platform integrating with ProVoyance
Risk Factors
- • Regulatory risk: CMS added total shoulder arthroplasty to ASC covered procedures list effective Jan 1, 2024, impacting Medicare reimbursement and ASC demand
- • Geopolitical/macro risk: No specific geopolitical risk disclosed; next material: seasonality with Q3 demand decline due to summer lifestyle impact
Financial SummaryXBRL
Revenue
$47M
Net Income
-$40M
Gross Margin
76.5%
Operating Margin
-55.6%
Net Margin
-85.3%
ROE
-28.7%
Total Assets
$170M
EPS (Diluted)
$-4.65
Operating Cash Flow
-$29M
Source: XBRL data from SHOULDER INNOVATIONS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SHOULDER INNOVATIONS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.